BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 6237081)

  • 1. A comparison of the ability of some radiosensitizers undergoing clinical trials to act as chemosensitizers.
    Hinchliffe M; McNally NJ
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1635-40. PubMed ID: 6237081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the effect of cytotoxic drugs by radiosensitizers.
    Martin WM; McNally NJ; De Ronde J
    Br J Cancer; 1981 Jun; 43(6):756-66. PubMed ID: 7248157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of timing on chemosensitization by clinical levels of SR-2508.
    Hirst DG; Horsman MR; Brown JM; Hazlehurst JL
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1641-5. PubMed ID: 6237082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of normal and malignant tissue to cyclophosphamide by nitroimidazoles with different partition coefficients.
    Hirst DG; Hazlehurst JL; Brown JM
    Br J Cancer; 1984 Jan; 49(1):33-42. PubMed ID: 6229264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
    Siemann DW
    Br J Cancer; 1982 Feb; 45(2):272-81. PubMed ID: 6460517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of cyclophosphamide cytotoxicity in vivo: a study with misonidazole and fifteen other 1-substituted 2-nitroimidazoles.
    Chaplin DJ; Sheldon PW; Ahmed I; Adams GE
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1647-51. PubMed ID: 6480452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of clinical levels of misonidazole on the response of tumour and normal tissues in the mouse to alkylating agents.
    Brown JM; Hirst DG
    Br J Cancer; 1982 May; 45(5):700-8. PubMed ID: 7082556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of the action of alkylating agents by single high, or chronic low doses of misonidazole.
    McNally NJ; Hinchliffe M; de Ronde J
    Br J Cancer; 1983 Aug; 48(2):271-8. PubMed ID: 6882665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069.
    Siemann DW; Maddison K; Wolf K
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1657-60. PubMed ID: 6548212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing the chemosensitization of melphalan by misonidazole.
    Randhawa VS; Stewart FA; Denekamp J; Stratford MR
    Br J Cancer; 1985 Feb; 51(2):219-28. PubMed ID: 3966979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxic cell radiosensitizers: expectations and progress in drug development.
    Coleman CN
    Int J Radiat Oncol Biol Phys; 1985 Feb; 11(2):323-9. PubMed ID: 3156109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depletion of glutathione in vivo as a method of improving the therapeutic ratio of misonidazole and SR 2508.
    Yu NY; Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1265-9. PubMed ID: 6236185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of alkylating agent induced cell kill by 2-nitroimidazoles in unclamped and clamped SC 9L tumors.
    Wallen CA; Moore SK; Wheeler KT
    Int J Radiat Oncol Biol Phys; 1992; 22(4):727-30. PubMed ID: 1531976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide.
    Law MP; Hirst DG; Brown JM
    Br J Cancer; 1981 Aug; 44(2):208-18. PubMed ID: 7272187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of 2-nitroimidazole radiosensitizers to cis-diamminedichloroplatinum(II) with radiation and with or without hyperthermia in the murine FSaIIC fibrosarcoma.
    Herman TS; Teicher BA; Holden SA; Pfeffer MR; Jones SM
    Cancer Res; 1990 May; 50(9):2734-40. PubMed ID: 2139359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms.
    Horsman MR; Evans JW; Brown JM
    Br J Cancer; 1984 Sep; 50(3):305-16. PubMed ID: 6466544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic potential of misonidazole enhancement of alkylating agent cytotoxicity.
    Hirst DG; Brown JM
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):639-42. PubMed ID: 7107389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies in radiosensitizing effects of misonidazole and SR-2508 on C3H/He mouse mammary tumors.
    Ono K; Takahashi M; Nishidai T; Dodo Y; Shibamoto Y; Hiraoka M; Yukawa Y; Abe M
    Radiat Med; 1984; 2(1):71-5. PubMed ID: 6242712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced tumor responses through therapies combining CCNU, MISO and radiation.
    Siemann DW; Hill SA
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1623-6. PubMed ID: 6480451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.